Canada markets closed
  • S&P/TSX

    20,188.43
    +90.91 (+0.45%)
     
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • DOW

    35,061.55
    +238.20 (+0.68%)
     
  • CAD/USD

    0.7961
    -0.0002 (-0.02%)
     
  • CRUDE OIL

    72.17
    +0.26 (+0.36%)
     
  • BTC-CAD

    41,937.33
    +1,087.66 (+2.66%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • GOLD FUTURES

    1,802.10
    -3.30 (-0.18%)
     
  • RUSSELL 2000

    2,209.65
    +10.17 (+0.46%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • NASDAQ

    14,836.99
    +152.39 (+1.04%)
     
  • VOLATILITY

    17.20
    -0.49 (-2.77%)
     
  • FTSE

    7,027.58
    +59.28 (+0.85%)
     
  • NIKKEI 225

    27,548.00
    +159.80 (+0.58%)
     
  • CAD/EUR

    0.6759
    -0.0001 (-0.01%)
     

FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - April 27, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=15176&wire=5

Allegations against FGEN include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you suffered a loss in FibroGen you have until June 11, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/81868

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting